ABSTRACT
The promise of personalized medicine is that each patient receives customized treatment from a broad base of options rather than a single, generalized standard of care treatment [1]. This is especially important in cancer where each patient's cancer could be viewed as a separate disease
caused by a unique set of aberrations. The rapidly decreasing cost of Next Generation Sequencing (NGS) is rendering this personalized approach a reality. For diseases with relatively high treatment costs, such as cancer, it is now economically viable to obtain whole genome sequencing data for the affected individual as part of the treatment regimen, and with further decreases in cost more and more diseases will follow suit.
